# Iododerma Following Radioactive Iodine Therapy in Thyroid Cancer: Insights From 2 Cases

**Authors:** Hawra Kamal, Julie Samantray

PMC · DOI: 10.1210/jcemcr/luaf056 · JCEM Case Reports · 2025-04-10

## TL;DR

This paper reports two rare cases of iododerma, a skin condition, following radioactive iodine therapy for thyroid cancer.

## Contribution

The study adds to the limited literature by presenting two new clinical cases of iododerma after radioactive iodine ablation.

## Key findings

- A 38-year-old female developed facial swelling and rashes that improved with prednisone.
- A 71-year-old male had a rash after iodine-131 therapy that resolved without treatment.
- Iododerma is a rare complication linked to iodine exposure and hypersensitivity reactions.

## Abstract

Radioactive iodine ablation is commonly used to treat thyroid diseases. However, despite its efficacy, it has inherent risks and complications. One such complication is iododerma. This rare dermatological condition triggered by iodine exposure has been infrequently documented in association with radioactive iodine therapy for thyroid diseases. Here, we present 2 cases of iododerma following radioactive iodine ablation for thyroid cancer. In the first case, a 38-year-old female developed facial swelling and red blotchy rashes accompanied by papules on the left upper eyelid. Despite initial worsening of symptoms, the patient improved after prednisone treatment. In the second case, a 71-year-old male with metastatic follicular thyroid cancer received iodine-131 therapy after levothyroxine withdrawal for pulmonary metastasis. Approximately 1 week posttherapy, he developed a nontender, nonpruritic rash on the extremities and anterior abdomen, which spontaneously resolved without intervention. Iododerma presents diagnostic challenges because of its rarity and diverse cutaneous manifestations. Although its exact pathophysiology remains unclear, it has been hypothesized to be induced by hypersensitivity reactions to and delayed clearance of iodine from the body. Physicians should be aware of this rare complication of radioactive iodine in patients with thyroid disease.

## Linked entities

- **Chemicals:** iodine (PubChem CID 807), iodine-131 (PubChem CID 5489939), levothyroxine (PubChem CID 5819), prednisone (PubChem CID 5865)
- **Diseases:** thyroid cancer (MONDO:0002108), follicular thyroid cancer (MONDO:0005034)

## Full-text entities

- **Diseases:** Thyroid Cancer (MESH:D013964), pulmonary metastasis (MESH:D009362), facial swelling (MESH:D004487), hypersensitivity (MESH:D004342), papules (MESH:D000169), thyroid disease (MESH:D013959), rash (MESH:D005076), follicular thyroid cancer (MESH:C572845)
- **Chemicals:** iodine-131 (MESH:C000614965), levothyroxine (MESH:D013974), iodine (MESH:D007455), Radioactive Iodine (-), prednisone (MESH:D011241)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11982607/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11982607/full.md

## References

13 references — full list in the complete paper: https://tomesphere.com/paper/PMC11982607/full.md

---
Source: https://tomesphere.com/paper/PMC11982607